These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 19074734)
1. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Norde WJ; Overes IM; Maas F; Fredrix H; Vos JC; Kester MG; van der Voort R; Jedema I; Falkenburg JH; Schattenberg AV; de Witte TM; Dolstra H Blood; 2009 Mar; 113(10):2312-23. PubMed ID: 19074734 [TBL] [Abstract][Full Text] [Related]
2. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791 [TBL] [Abstract][Full Text] [Related]
3. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Overes IM; de Rijke B; van Horssen-Zoetbrood A; Fredrix H; de Graaf AO; Jansen JH; van Krieken JH; Raymakers RA; van der Voort R; de Witte TM; Dolstra H Br J Haematol; 2008 Jun; 141(6):799-807. PubMed ID: 18410452 [TBL] [Abstract][Full Text] [Related]
4. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells. Overes IM; Fredrix H; Kester MG; Falkenburg JH; van der Voort R; de Witte TM; Dolstra H J Immunother; 2009; 32(6):539-51. PubMed ID: 19483655 [TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. Overes IM; Levenga TH; Vos JC; van Horssen-Zoetbrood A; van der Voort R; De Mulder PH; de Witte TM; Dolstra H Cancer Immunol Immunother; 2009 Mar; 58(3):429-39. PubMed ID: 18719914 [TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460 [TBL] [Abstract][Full Text] [Related]
7. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982 [TBL] [Abstract][Full Text] [Related]
8. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616 [TBL] [Abstract][Full Text] [Related]
9. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568 [TBL] [Abstract][Full Text] [Related]
10. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Bonnet D; Warren EH; Greenberg PD; Dick JE; Riddell SR Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8639-44. PubMed ID: 10411928 [TBL] [Abstract][Full Text] [Related]
11. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986 [TBL] [Abstract][Full Text] [Related]
12. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962 [TBL] [Abstract][Full Text] [Related]
13. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056 [TBL] [Abstract][Full Text] [Related]
14. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495 [TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279 [TBL] [Abstract][Full Text] [Related]
16. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Gao L; Bellantuono I; Elsässer A; Marley SB; Gordon MY; Goldman JM; Stauss HJ Blood; 2000 Apr; 95(7):2198-203. PubMed ID: 10733485 [TBL] [Abstract][Full Text] [Related]
17. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Niederwieser D; Grassegger A; Auböck J; Herold M; Nachbaur D; Rosenmayr A; Gächter A; Nussbaumer W; Gaggl S; Ritter M Blood; 1993 Apr; 81(8):2200-8. PubMed ID: 8471780 [TBL] [Abstract][Full Text] [Related]
18. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction. van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556 [TBL] [Abstract][Full Text] [Related]
19. The clinical implications of mixed lymphocyte reaction with leukemic cells. Kim HJ; Kim TG; Cho HI; Han H; Min WS; Kim CC Int J Hematol; 2002 Nov; 76(4):370-5. PubMed ID: 12463603 [TBL] [Abstract][Full Text] [Related]
20. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]